BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

VolverVolver

Resultados 55 resultados LastUpdate Última actualización 17/08/2019 [17:34:00] pdf PDF

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days

Página1 de 3 nextPage   por página


ANTIBODY BASED REAGENTS THAT SPECIFICALLY RECOGNIZE NEURODEGENERATIVE DISEASE RELATED FORMS OF THE PROTEIN TDP-43

NºPublicación: US2019250171A1 15/08/2019

Solicitante:

UNIV ARIZONA STATE [US]

US_2017010284_A1

Resumen de: US2019250171A1

The invention relates to antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with frontotemporal dementia (FTD), but not TDP-43 associated with amyotrophic lateral sclerosis (ALS) or TDP-43 associated with healthy human brain tissue, and antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with ALS, but not TDP-43 associated FTD or TDP-43 associated with healthy human brain tissue.

traducir

COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDER

NºPublicación: US2019242909A1 08/08/2019

Solicitante:

BERG LLC [US]

JP_2018153184_A

Resumen de: US2019242909A1

Methods for treatment and diagnosis of pervasive developmental disorders in humans are described.

traducir

STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION

NºPublicación: US2019241613A1 08/08/2019

Solicitante:

UNIV CALIFORNIA [US]

KR_20190034214_A

Resumen de: US2019241613A1

This invention relates to inhibitory peptides which bind to α-synuclein molecules and inhibit α-synuclein amyloidogenic aggregation, α-synuclein cytotoxicity, and spread of α-synuclein. Methods of making and using the inhibitory peptides (e.g. to treat subjects having conditions or diseases that are mediated by α-synuclein, such as Parkinson's disease, dementia with Lewy bodies, or MSA) are described.

traducir

HUMAN ANTI-ALPHA-SYNUCLEIN ANTIBODIES

NºPublicación: EP3521309A1 07/08/2019

Solicitante:

BIOGEN INT NEUROSCIENCE GMBH [CH]
UNIV OF ZURICH [CH]

US_2018371065_A1

Resumen de: EP3521309A1

Provided are novel human α-synuclein-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.

traducir

ASSAY FOR DIAGNOSING ALZHEIMER'S DISEASE

NºPublicación: EP3519829A1 07/08/2019

Solicitante:

KING S COLLEGE LONDON [GB]

US_2019227083_A1

Resumen de: WO2018060709A1

The invention disclosed herein is for an in vitro cell-based assay for predicting the conversion from mild cognitive impairment to Alzheimer's disease in a patient who has received a diagnosis of MCI. The method comprises the following steps: a) culturing human hippocampal progenitor cells in a culture medium comprising serum, obtained from said patient, during a period of proliferation of said progenitor cells; b) subsequently culturing said hippocampal progenitor cells in a culture medium comprising serum, obtained from said patient, during a period of differentiation of said progenitor cells; c) determining the level of proliferation of said cultured progenitor cells; d) determining the average cell count of said cultured progenitor cells; and e) monitoring apoptotic cell death after differentiation of the proliferated hippocampal progenitor cells, wherein the outcomes of each of (c) to (e) are applied to a statistical analysis, the result of which is predictive of conversion from MCI to AD in the patient.

traducir

METHOD FOR DETECTING SMALL RNAS OR PROTEINS ASSOCIATED WITH SMALL RNAS

NºPublicación: EP3521450A1 07/08/2019

Solicitante:

NURIBIO CO LTD [KR]

US_2019226033_A1

Resumen de: EP3521450A1

The present invention relates to a method for detecting small RNA or small RNA-associated protein, and more particularly to a method of detecting small RNA or small RNA-associated protein using a promer, which has the structure X-Y-Z and comprises a nucleotide sequence capable of binding complementarily to the whole or a part of the small RNA to be detected. The present invention makes it possible to rapidly and accurately detect the small RNA or the small RNA-associated protein, and thus may be advantageously used for diagnosis of various diseases and prognostic prognosis.

traducir

COMPOSITIONS, METHODS AND KITS FOR DETECTION OF GENETIC VARIANTS FOR ALZHEIMER'S DISEASE

NºPublicación: CN110100014A 06/08/2019

Solicitante:

\u9999\u6E2F\u79D1\u6280\u5927\u5B66

US_2018142287_A1

Resumen de: WO2018077303A1

Provided herein are methods, kits, and devices related to genetic variations of neurological disorders. For example, methods, kits, and devices for using such genetic variations to assess susceptibility of developing Alzheimer's disease.

traducir

NEUROTOXIC TARGET FOR AMYLOSPHEROID, METHOD AND MATERIAL FOR REDUCING THE NEUROTOXICITY OF AMYLOSPHEROID, AND USE THEREOF

NºPublicación: CN110075111A 02/08/2019

Solicitante:

\u9053\u5065\u5EB7\u751F\u6D3B\u533B\u836F\u682A\u5F0F\u4F1A\u793E

TW_201829444_A

Resumen de: US2013171069A1

In one or a plurality of embodiments, there is provided a target molecule of amylospheroid, which is expressed in mature neurons and to which the amylospheroid binds to induce death of cells. Further, in one or a plurality of embodiments, there is provided a method and a substance for inhibiting death of mature neurons induced by the amylospheroid. In one aspect, the present disclosure relates to a use of Na+/K+-ATPase alpha3 as a binding target molecule of amylospheroid. In another aspect, the present disclosure relates to a method for suppressing death of mature neurons induced by the amylospheroid, including inhibiting protein-protein interaction between the amylospheroid and the Na+/K+-ATPase alpha3, and the like.

traducir

COMPOSITIONS AND METHODS RELATED TO THE METHYLATION OF HISTONE H1.0 PROTEIN

NºPublicación: US2019234948A1 01/08/2019

Solicitante:

AELAN CELL TECH INC [US]

CN_109415431_A

Resumen de: US2019234948A1

Provided herein are compositions and methods related to the production and detection of a histone H1.0 protein dimethylated at lysine residue 180 (K180) (H1.0K180me2 protein) or a histone H1.0 peptide dimethylated at a lysine residue corresponding to K180 (H1.0K180me2 peptides). The H1.0K180me2 protein and H1.0K180me2 peptides are useful for applications including, but not limited to, molecular diagnostics of DNA damage, genotoxic stress, radiation exposure, and Alzheimer's disease, therapeutics, monitoring of therapeutic regimens, patient stratification, and drug screening. Also provided herein are antibodies specific for the H1.0K180me2 protein and H1.0K180me2 peptides.

traducir

Blood Test for Screening Out Amyloid and Alzheimers Disease Presence

NºPublicación: US2019234967A1 01/08/2019

Solicitante:

UNIV OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH [US]

AU_2017281229_A1

Resumen de: US2019234967A1

The present invention includes a method for excluding patients from the need for further analysis of Alzheimer's Disease comprising: obtaining a blood or serum sample from a patient in a primary care setting; determining the expression levels of at least 4 of the following proteins: FABP, beta 2 microglobulin, PPY, soluble tumor necrosis factor receptor 1 (sTNFR1), CRP, VCAM-1, thrombopoietin, α2 macroglobulin, eotaxin 3, tumor necrosis factor-alpha (TNF-α), tenascin C (TNC), IL-5, IL-6, IL-7, IL-10, IL-18, 1309, Factor VII, thymus and activation-regulated chemokine (TARC), serum amyloid A (SAA), and intercellular cell-adhesion molecule-1 (ICAM-1); comparing the level of expression from the sample with a statistically locked-down, multi-ethnic, broad age spectrum statistical sample; and determining if the patient is excluded from further testing for Alzheimer's Disease, thereby eliminating the need for further testing of the patient.

traducir

METHODS OF DIAGNOSIS ALZHEIMER'S DISEASE

NºPublicación: US2019233894A1 01/08/2019

Solicitante:

ECOLE POLYTECHNIQUE FED LAUSANNE EPFL [CH]
FUNDACIO PRIVADA INST DE RECERCA BIOMEDICA DE BELLVITGE [ES]
FUNDACIO INST CATALANA DE RECERCA I ESTUDIS AVANCATS ICREA [ES]

WO_2018015291_A1

Resumen de: US2019233894A1

A method for the diagnosis or prognosis of Alzheimer's disease (AD), includes the steps of placing a sample isolated from a person suspected of having AD onto a substrate labeling the sample to identify at least one epigenetic marker and/or genetic variation and determining a state of AD. One of the epigenetic markers is PM20D1 promoter DNA methylation and/or one of the genetic variation is in at least one of PM20D1 mQTL-associated SNPs. PM20D1 is used as a therapeutic target and viral vectors encoding PM20D1 are used in the therapy of AD. Moreover, a kit for diagnosing AD includes reagents for detecting the SNPs rs708727, rs947211, rs708730, rs708724 or rs823130.

traducir

DIAGNOSTIC DEVICES AND METHODS OF USE

NºPublicación: US2019234968A1 01/08/2019

Solicitante:

DIGNITY HEALTH [US]

US_2017089925_A1

Resumen de: US2019234968A1

The present invention relates to methods of diagnosing samples as well as various microfluidic, microcentrifuge and microfilter devices. In one embodiment, the present invention provides a method of diagnosing neurodegenerative diseases using mitochondrial and/or platelet samples. In another embodiment, the present invention provides a microfluidic device that selectively captures and analyzes a desired amount of target biological particle.

traducir

METHODS AND COMPOSITIONS FOR TAUOPATHY DIAGNOSIS AND TREATMENT

NºPublicación: US2019234966A1 01/08/2019

Solicitante:

CHILDRENS MEDICAL CENTER [US]

WO_2017053739_PA

Resumen de: US2019234966A1

This disclosure relates to methods of determining the amount of post translational modification (PTM) associated with one or more tau peptide fragments of a tau protein in a sample, and methods of evaluating a subject for having a tauopathy, the methods comprising, in part, determining the amount of post translational modification (PTM) associated with one or more tau peptide fragments of a tau protein in a sample, and comparing the amount of the tau PTMs associated with one or more tau peptide fragments with one or more reference levels for the tau peptide fragments, thereby determining whether a subject has a tauopathy.

traducir

АНТИТЕЛА, СПЕЦИФИЧНЫЕ К ГИПЕРФОСФОРИЛИРОВАННОМУ ТАУ-БЕЛКУ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

NºPublicación: EA201892570A1 31/07/2019

Solicitante:

\u0425. \u041B\u0423\u041D\u0414\u0411\u0415\u041A\u041A \u0410/\u0421

Resumen de: EA201892570A1

Настоящее изобретение относится к классу моноклональных антител, которые специфически связываются с фосфорилированным сериновым остатком 396 в патологическом гиперфосфорилированном (PHF) тау-белке (pS396) с улучшенной аффинностью, а также к способам применения этих молекул и их фрагментов, связывающих тау-белок, в лечении болезни Альцгеймера и других таупатий.

traducir

COMBINED ASSAY FOR THE DIFFERENTIAL DIAGNOSIS OF THE ALZHEIMER'S DISEASE

NºPublicación: KR20190089928A 31/07/2019

Solicitante:

RUHR UNIV BOCHUM [DE]

AU_2017360097_A1

Resumen de: EP3324187A1

The invention provides a combined immuno-infrared assay for the differential diagnosis and sub classification of Alzheimer's disease into different disease stages. The method can be applied for assured disease diagnostics and patient stratification. The assay considers the label-free detection of the change within the Amyloid-beta peptide and Tau protein secondary structure distribution in bodily fluids. This secondary structure change from native to ß-sheet enriched isoforms appears years before clinical disease manifestation. Now, the combined method utilizes this shift for diagnostics based on liquid biopsies.

traducir

Methods for the treatment of neurological disorders

NºPublicación: AU2018205275A1 25/07/2019

Solicitante:

YUMANITY THERAPEUTICS INC

WO_2018129403_A1

Resumen de: AU2018205275A1

The present disclosure provides compounds and methods useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

traducir

ASSAY FOR DIAGNOSING ALZHEIMER'S DISEASE

NºPublicación: US2019227083A1 25/07/2019

Solicitante:

KING S COLLEGE LONDON [GB]

WO_2018060709_PA

Resumen de: US2019227083A1

The invention disclosed herein is for an in vitro cell-based assay for predicting the conversion from mild cognitive impairment to Alzheimer's disease in a patient who has received a diagnosis of MCI. The method comprises the following steps: a) culturing human hippocampal progenitor cells in a culture medium comprising serum, obtained from said patient, during a period of proliferation of said progenitor cells; b) subsequently culturing said hippocampal progenitor cells in a culture medium comprising serum, obtained from said patient, during a period of differentiation of said progenitor cells; c) determining the level of proliferation of said cultured progenitor cells; d) determining the average cell count of said cultured progenitor cells; and e) monitoring apoptotic cell death after differentiation of the proliferated hippocampal progenitor cells, wherein the outcomes of each of (c) to (e) are applied to a statistical analysis, the result of which is predictive of conversion from MCI to AD in the patient.

traducir

Promer for Real-Time Detection of Nucleic Acid or Protein and Method of detecting Nucleic Acid or Protein Using the Same

NºPublicación: US2019226033A1 25/07/2019

Solicitante:

NURIBIO CO LTD [KR]

CN_110023507_A

Resumen de: US2019226033A1

A method for detecting small RNA or small RNA-associated protein, and more particularly to a method of detecting small RNA or small RNA-associated protein using a promer is provided. It has the structure X-Y-Z and has a nucleotide sequence capable of binding complementarily to the whole or a part of the small RNA to be detected. The present invention makes it possible to rapidly and accurately detect the small RNA or the small RNA-associated protein, and thus may be advantageously used for diagnosis of various diseases and prognostic prognosis.

traducir

Curcumin Derivative, Method for Producing Same, and Photo-Acoustic Imaging Agent Comprising Same for Detecting Beta-Amyloid Plaque

NºPublicación: US2019224344A1 25/07/2019

Solicitante:

KOREA ATOMIC ENERGY RES [KR]

CN_109790184_A

Resumen de: US2019224344A1

The present invention relates to a curcumin derivative, a method for producing same, and a photo-acoustic imaging agent comprising the curcumin derivative for detecting beta-amyloid plaque. The curcumin derivative, expressed by chemical formula 1, according to the present invention exhibits superb selective bonding with beta-amyloid, thereby allowing beta-amyloid to be detected by means of an optical or photo-acoustic imaging methods, and, particularly, the curcumin derivative can highly effectively detect photo-acoustic signals with almost no noise by reacting to irradiation of light having a particular wavelength range, and thus can be useful as a composition for detecting beta-amyloid and for diagnosing diseases caused by excessive production of beta-amyloid.

traducir

Protein Damage in Aging and Age-Related Diseases

NºPublicación: US2019227058A1 25/07/2019

Solicitante:

MEDITERRANEAN INST FOR LIFE SCIENCES [HR]

US_2018217133_A1

Resumen de: US2019227058A1

The process of aging and the development of age-related diseases are related to the emerging phenotypes of increasingly damaged and progressively malfunctioning proteomes. The present invention provides methods of preventing aging and age-related diseases in mammals by assessment of protein-specific oxidative damage. Methods of providing treatments that reduce intracellular reactive oxygen and/or nitrogen species, or protein-specific damage caused by reactive oxygen and/or nitrogen species, are disclosed. Furthermore, methods of screening for compounds that reduce intracellular reactive oxidative species, and/or molecules that prevent protein-specific damage by protecting the susceptible protein from such damage and therefore prevent or treat degenerative or age-related diseases, are also disclosed.

traducir

PHENOTYPIC AGE AND DNA METHYLATION BASED BIOMARKERS FOR LIFE EXPECTANCY AND MORBIDITY

NºPublicación: WO2019143845A1 25/07/2019

Solicitante:

UNIV CALIFORNIA [US]
NAT INSTITUTES OF HEALTH [US]

Resumen de: WO2019143845A1

Identifying reliable biomarkers of aging is a major goal in geroscience. While the first generation of epigenetic biomarkers of aging were developed using chronological age as a surrogate for biological age, we hypothesized that composite clinical measures of "phenotypic age", may facilitate the development of a more powerful epigenetic biomarker of aging. Here we show that our newly developed epigenetic biomarker of aging "DNAm PhenoAge" strongly outperforms previous measure in regards to predictions for a variety of aging outcomes, including all-cause mortality, cancers, physical functioning, and, age-related dementia. It is also associated with Down syndrome, HIV infection, socioeconomic status, and various life style factors such as diet, exercise, and smoking. Overall, this single epigenetic biomarker of aging is able to capture risks for an array of diverse outcomes across multiple tissues and cells, and in moving forward, will facilitate the development of anti-aging interventions.

traducir

COMPANION DIAGNOSTIC FOR NSAIDS AND DONEPEZIL FOR TREATING SPECIFIC SUBPOPULATIONS OF PATIENTS SUFFERING FROM ALZHEIMER'S DISEASE

NºPublicación: WO2019143562A1 25/07/2019

Solicitante:

UNIV OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH [US]

Resumen de: WO2019143562A1

The present invention includes a method for identifying a patient response to treatment for Alzheimer's Disease with a non-steroidal anti-inflammatory drug (NSAID) or an acetylcholinesterase (AChE) inhibitor drug comprising: obtaining a blood or serum sample from the patient; determining the presence of a proinflammatory endophenotype in the blood or serum sample of the patient; using the proinflammatory endophenotype to detect treatment response (a responder, a stable, a non-responder or an adverse responder); and treating the patient with the NSAID or the AChE inhibitor if the patient is in the responder or the stable treatment response phenotype group; or preventing a treatment with the NSAID or the AChE inhibitor if the patient is a non-responder or an adverse responder.

traducir

METHOD FOR DETERMINING RISK OF ALZHEIMER'S DISEASE

NºPublicación: JPWO2018084242A1 25/07/2019

Solicitante:

\u56FD\u7ACB\u5927\u5B66\u6CD5\u4EBA\u4E5D\u5DDE\u5927\u5B66,
\u516C\u76CA\u793E\u56E3\u6CD5\u4EBA\u4E45\u5C71\u751F\u6D3B\u7FD2\u6163\u75C5\u7814\u7A76\u6240

WO_2018084242_A1

Resumen de: WO2018084242A1

According to the present invention, the presence or absence of a risk of acquiring Alzheimer's disease or an onset risk thereof can be determined by measuring glycoalbumin and hemoglobin A1c in a blood sample and calculating a glycoalbumin/hemoglobin A1c ratio. By using the glycoalbumin/hemoglobin A1c ratio, moreover, a compound for treating or preventing Alzheimer's disease can be screened.

traducir

COMPOSITION FOR SCREENING ONGOING PROGRESS OF ALZHEIMER'S DISEASE BY USING BETA AMYLOID OLIGOMER IN NASAL DISCHARGE SPECIMEN AND METHOD FOR SCREENING ONGOING PROGRESS OF ALZHEIMER'S DISEASE BY USING SAME

NºPublicación: WO2019143125A1 25/07/2019

Solicitante:

DAEGU GYEONGBUK INSTITUE OF SCIENCE AND TECH [KR]

KR_101868343_B1

Resumen de: WO2019143125A1

The present invention relates to a composition for screening an ongoing progress of Alzheimer's disease by using beta amyloid in a nasal discharge specimen and a method for screening an ongoing progress of Alzheimer's disease by using the same and, more particularly, to a composition and a kit for screening an ongoing progress of Alzheimer's disease, the composition and the kit each comprising an agent for measuring expression levels of a 56 kDa beta amyloid oligomer and a 72 kDa beta amyloid oligomer in a nasal discharge specimen, and a method for screening an ongoing progress of Alzheimer's disease, the method comprising a step of measuring expression levels of 56 kDa and 72 kDa beta amyloid oligomers in a nasal discharge specimen.

traducir

BLOOD-BASED SCREEN FOR DETECTING NEUROLOGICAL DISEASES IN PRIMARY CARE SETTINGS

Nº publicación: US2019219599A1 18/07/2019

Solicitante:

UNIV OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH [US]
UNIV TEXAS [US]

Resumen de: US2019219599A1

The present invention includes methods and kits for measuring a level of four or more biomarkers selected from IL1, IL7, TNFα, IL5, IL6, CRP, IL10, TNC, ICAM1, FVII, I309, TNFR1, A2M, TARC, adiponectin, MIP1, eotaxin3, sVCAM1, TPO, FABP, IL18, B2M, SAA, PPY, DJ1, α-synuclein, Ab40, Ab42, tau, alpha-syn, and NfL in a sample separated from a human subject in the primary care setting with neurological disease with a nucleic acid, an immunoassay or an enzymatic activity assay.

traducir

Página1 de 3 nextPage por página

punteroimgVolver